Quick Answer
Denali Therapeutics Inc. reported Operating Income of -$555.34 million for fiscal year 2025.
Denali Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$555.34M | -14.0% |
| 2024 | -$487.34M | -147.8% |
| 2023 | -$196.70M | +42.3% |
| 2022 | -$340.74M | -15.2% |
| 2021 | -$295.75M | -571.6% |
| 2020 | $62.72M | +129.4% |
| 2019 | -$213.18M | -359.7% |
| 2018 | -$46.37M | +48.6% |
| 2017 | -$90.14M | -3.1% |
| 2016 | -$87.43M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$137.43M | -11.6% | -1.8% |
| June 30, 2025 | -$134.96M | -15.8% | +7.3% |
| March 31, 2025 | -$145.58M | -23.7% | -18.2% |
| September 30, 2024 | -$123.19M | -8.3% | -5.7% |
| June 30, 2024 | -$116.59M | -168.4% | +1.0% |
| March 31, 2024 | -$117.72M | +2.6% | -3.4% |
| September 30, 2023 | -$113.80M | -5.9% | -166.7% |
| June 30, 2023 | $170.48M | +377.6% | +241.1% |
- Denali Therapeutics Inc. showed a decrease of -14.0% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Denali Therapeutics Inc.’s operating income has declined by 535.2% (from -$87.43 million to -$555.34 million).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: